Literature DB >> 18923371

Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma.

M R Pelizzo1, I Merante Boschin, A Toniato, C Pagetta, E Casal Ide, C Mian, D Rubello.   

Abstract

The papillary thyroid carcinoma (PTC) is the most frequent endocrine cancer and it is the most common thyroid cancer (85-95%). Potential risk factors for the incidence of the PTC include radiation exposure, iodine deficiency, family history of thyroid cancer. The PTC is usually indolent and the prognosis is favourable, with a 10 year survival generally reported to exceed 90%. The palpation and growth of thyroid nodules are the more frequent clinical manifestations of the PTC which can be evaluated by physical examination, neck ultrasound and fine needle aspiration cytology (FNAC). The therapeutic management of PTC includes surgical treatment combined with 131I therapy and life long TSH suppressive thyroid hormone replacement. The external beam radiation can be taken into account in select aggressive tumours. Nevertheless the good prognosis of the PTC, the prevalence of persistence or recurrent disease is not trans-curable. The biomolecular studies can permit to individuate the more aggressive PTC subtypes. A more significant attention of the clinical examination, US and FNAC to the thyroid nodular disease will be able to guarantee a more precocious diagnosis and a radical surgical treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923371

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  22 in total

1.  Skull metastasis in papillary carcinoma of thyroid: A case report.

Authors:  Akshay Nigam; Ajay K Singh; Sanjeev K Singh; Neelima Singh
Journal:  World J Radiol       Date:  2012-06-28

2.  Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.

Authors:  Qing Xia; Shuai Dong; Ping-Da Bian; Jue Wang; Cheng-Jiang Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-06       Impact factor: 2.503

3.  Features of papillary thyroid carcinoma in patients older than 75 years.

Authors:  Antonio Toniato; Chiara Bernardi; Andrea Piotto; Domenico Rubello; Maria Rosa Pelizzo
Journal:  Updates Surg       Date:  2011-03-17

4.  Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases.

Authors:  Jeong Won Lee; Hye Sook Min; Sang Mi Lee; Hyun Woo Kwon; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2015-02-13

5.  Chromatin changes in papillary thyroid carcinomas may predict patient outcome.

Authors:  R C Ferreira; L L Cunha; P S Matos; R L Adam; F Soares; J Vassallo; L S Ward
Journal:  Cell Oncol (Dordr)       Date:  2012-12-05       Impact factor: 6.730

6.  Prognostic values of thyroid tumours.

Authors:  Suzana Manxhuka-Kerliu; Emine Devolli-Disha; Arsim Gerxhaliu; Halil Ahmetaj; Arijeta Baruti; Sadushe Loxha; Hajdin Thaqi
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

7.  What do we leave behind after neartotal and subtotal thyroidectomy: just the tissue or the disease?

Authors:  Rojbin Karakoyun; Nurullah Bülbüller; Savaş Koçak; Mani Habibi; Umut Gündüz; Bekir Erol; Osman Oner; Arif Aslaner; Dinç Sürer; Sükrü Ozdemir; Hakan Gülkesen
Journal:  Int J Clin Exp Med       Date:  2013-10-25

8.  Value of sentinel lymph node biopsy in papillary thyroid cancer: initial results of a prospective trial.

Authors:  R N Cabrera; C T Chone; D Zantut-Wittmann; P Matos; D M Ferreira; P S G Pereira; R J R Ferrari; A O Santos; A N Crespo; E C S C Etchebehere
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-03       Impact factor: 2.503

9.  Discovery and identification of potential biomarkers of papillary thyroid carcinoma.

Authors:  Yuxia Fan; Linan Shi; Qiuliang Liu; Rui Dong; Qian Zhang; Shaobo Yang; Yingzhong Fan; Heying Yang; Peng Wu; Jiekai Yu; Shu Zheng; Fuquan Yang; Jiaxiang Wang
Journal:  Mol Cancer       Date:  2009-09-28       Impact factor: 27.401

10.  MiR-181a promotes cell proliferation and migration through targeting KLF15 in papillary thyroid cancer.

Authors:  C X Sun; B J Liu; Y Su; G W Shi; Y Wang; J F Chi
Journal:  Clin Transl Oncol       Date:  2021-07-26       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.